AI & Pharma: Revolutionizing Drug Discovery 🚀💡

CHAPTER 1: AWS and Novo Nordisk Forge a Strategic AI Partnership
Novo Nordisk is expanding its use of AWS artificial intelligence tools across drug discovery, including AI agents for target identification, therapy design, and research workflows. Under the agreement announced recently, AWS will become Novo Nordisk’s preferred cloud provider and strategic AI partner. The companies have also created a co-innovation hub at Novo Nordisk’s existing London facility, where AWS engineers and Novo Nordisk scientists will work directly with the pharmaceutical company’s data and research insights. The London hub will bring Novo Nordisk R&D staff together with AWS engineers, AI specialists, applied scientists, and professional services teams.

CHAPTER 2: Operationalizing AI: Expanding Existing Deployments
Novo Nordisk already uses AWS technology across internal AI workloads. According to an AWS case study, more than 25,000 Novo Nordisk employees have used a generative AI platform built on Amazon Bedrock to create chatbots covering more than 2,500 use cases. Those applications include information retrieval and document drafting across non-regulated processes. One of the larger deployments uses a collection of about 140,000 documents and processes more than 26,000 prompts each month, according to AWS. Novo Nordisk has also applied generative AI to clinical-study documentation. AWS said a system using Anthropic’s Claude 3.5 through Amazon Bedrock reduced the time required to generate some clinical documentation by more than 90%.

CHAPTER 3: Leveraging Amazon Bio Discovery and Agentic AI
Novo Nordisk plans to use the service for tasks including identifying potential drug targets, designing therapies, and analysing biological information. The platform can also generate and rank potential drug candidates before selected candidates are sent for laboratory synthesis and testing. Experimental results can then be returned to the computational workflow for further analysis and model refinement. This links computational drug design with physical testing in the same research workflow. Novo Nordisk will also use Amazon Bedrock to build AI applications that can work across clinical, genomic, and imaging datasets. According to the companies, connecting these data sources is intended to allow findings from early-stage research to inform clinical trial design.

CHAPTER 4: Integrating Data and Accelerating Drug Discovery
The partnership combines Novo Nordisk’s research in chronic diseases with AWS cloud infrastructure, AI services, and life sciences technologies. AI enters more research workflows. AWS Forward Deployed Engineers will also work directly with Novo Nordisk teams on the systems developed through the partnership. The programme embeds AWS technical staff with customers to work on AI projects, including agent-based applications. The agreement builds on a broader relationship between Novo Nordisk and Amazon that also includes Amazon Pharmacy, Amazon Ads, and One Medical.

CHAPTER 5: Expanding the Ecosystem and Future Collaborations
AWS has separately announced life sciences AI collaborations with Flagship Pioneering and Johnson & Johnson in 2026. Novo Nordisk has also pursued AI projects outside AWS. The company has worked with OpenAI on deploying artificial intelligence across areas including drug discovery, manufacturing, and commercial operations. It has also signed on to use Denmark’s Gefion supercomputer. The system provides computing capacity for workloads including AI model development and other data-intensive scientific research.